论文部分内容阅读
目的:通过采用痰热清联合阿奇霉素治疗支原体肺炎来观察其临床治疗效果及安全性,从而为患者治疗选择提供最佳选择。方法:选取2010年5月—2012年5月60例支原体肺炎患者按照治疗方法不同分组为对照组与观察组,分别为30例。其中对照组:成年采用0.5 g阿奇霉素+500 m L生理盐水,静脉滴注治疗;小儿采用阿奇霉素10 mg/(kg·d)静脉滴注,连续使用5天,滴注时间>3 h,治疗5天后口服阿奇霉素,10 mg/(kg·d),1次/d,连续使用3天,停用4天后再服用3天。观察组于对照组治疗基础上采用痰热清注射液治疗,小儿采用0.3~0.5 m L/kg痰热清+5%葡萄糖溶液100~200 m L,静脉滴注,1次/d;成年采用20 m L痰热清+5%葡萄糖溶液500 m L,静脉滴注,1次/d。比较两组临床疗效、临床症状改善、住院时间、不同年龄及性别治疗效果、不良反应。结果:经治疗后,观察组治疗有效者(痊愈+显效+有效)28例,占93.3%明显高于对照组22例,占73.3%,具有统计学意义,P<0.05;观察组咳嗽等临床症状改善时间及平均住院时间明显短语对照组,具有统计学意义,P<0.05。两组不同年龄及性别间疗效比较,差异显著,具有统计学意义,P<0.05;两组治疗期间未见明显性不良反应。结论:相比单纯阿奇霉素治疗来说,采用痰热清注射液联合阿奇霉素治疗不同年龄及性别患者,可有效改善其临床症状,促进其康复,提高临床疗效,缩短患者住院时间,且无明显不良反应发生。因此值得进一步推广应用。
Objective: By using Tanreqing combined with azithromycin treatment of mycoplasma pneumonia to observe its clinical efficacy and safety, so as to provide the best choice for the treatment of patients. Methods: From May 2010 to May 2012, 60 patients with mycoplasmal pneumonia were divided into control group and observation group according to the different treatment methods, respectively, 30 cases. In the control group, 0.5g azithromycin + 500ml normal saline was used in adults, and was treated by intravenous drip. Pediatric patients were treated with azithromycin 10 mg / (kg · d) Days after oral azithromycin, 10 mg / (kg · d), 1 / d, continuous use of 3 days, 4 days off and then take 3 days. The observation group was treated with Tanreqing Injection on the basis of the control group. Infants were treated with 0.3 ~ 0.5 m L / kg Tanreqing + 5% dextrose solution 100 ~ 200 mL, 20 m L Tanreqing + 5% glucose solution 500 m L, intravenous infusion, 1 / d. The clinical curative effect, clinical symptom improvement, hospitalization time, treatment effect of different age and sex, adverse reactions were compared between the two groups. Results: After treatment, the observation group of effective treatment (cured + effective + effective) 28 cases, accounting for 93.3% was significantly higher than the control group 22 cases, accounting for 73.3%, with statistical significance, P <0.05; observation group cough and other clinical Symptom improvement time and average length of stay obvious phrase control group, with statistical significance, P <0.05. There were significant differences between the two groups in curative effect of different age and gender, with statistical significance (P <0.05). No significant adverse reactions were found in the two groups during the treatment. Conclusion: Compared with simple azithromycin treatment, Tanreqing injection combined with azithromycin in patients of different ages and genders can effectively improve its clinical symptoms and promote its rehabilitation, improve clinical efficacy, shorten the hospital stay, and no significant adverse reactions occur. It is worth further promotion and application.